Quadrant Biosciences CEO Rich Uhlig named one of the top 50 CEOs in health technology
CEO Richard Uhlig recognized for exemplary leadership during global pandemic
SYRACUSE, NY, UNITED STATES, April 15, 2021 /EINPresswire.com/ – Quadrant Biosciences Inc., a leading developer of new molecular diagnostic tools, announced that CEO Richard Uhlig has been recognized as one of the Top 50 Health Technology CEOs of 2021 by The Healthcare Technology Report. Uhlig was recognized for his outstanding leadership and guidance amid the global pandemic, which included the development of a highly sensitive q-PCR saliva test for COVID-19[female[feminine.
According to the Health Technology Report, âThe award recognizes some of the most accomplished leaders in health technology whose leadership has been essential in the development of cutting-edge medical devices, next-generation software platforms and diagnostics. advanced, and recognizes the unique opportunities for transformation and growth within their areas of expertise.
Quadrant, in partnership with SUNY Upstate Medical University, developed the Clarifi COVID-19 Saliva Test Kit in 2020 in response to the demand for highly sensitive, saliva-based COVID-19 testing. The Clarifi COVID-19 test kit, which received emergency use clearance from the FDA in September 2020, is currently classified by the FDA as the most sensitive saliva test on the market and has been administered over ‘a million times. The company has also developed Clarifi ASDÂ®, a new molecular saliva test for autism spectrum disorders. Research and development of molecular diagnostic tests for mild traumatic brain injury and Parkinson’s disease are ongoing.
âIt is an honor to receive this award and to share this recognition with such luminaries in the health technology field,â said Richard Uhlig, CEO of Quadrant Biosciences. âThe development of the Clarifi COVID-19 assay has been a prime example of our ability to agilely apply our growing expertise in RNA analysis to an urgent healthcare need and to quickly bring together the resources to develop a solution. The coronavirus has had a devastating effect on health and well-being around the world, so it is extremely gratifying for us to use the expertise we have gained from working on diagnostic RNA tests to other health issues, such as autism spectrum disorders and concussions, and to apply this expertise to the development of this critically important test. “
About Quadrant Biosciences
Quadrant Biosciences is a life sciences company that develops molecular diagnostic solutions for large-scale health problems. The company has forged collaborative research relationships with a number of institutions, including SUNY Upstate Medical University and Penn State University, to explore and develop new biomarker technologies with a focus on autism spectrum disorders, concussions and Parkinson’s disease. Recently, he used his expertise in RNA analysis to deal with the COVID-19 pandemic. Quadrant participates in the Start-up NY program, a New York State economic development program. For more information on Quadrant, please visit www.quadrantbiosciences.com.
About emergency use authorization status
The Clarifi COVID-19 test kit has not been authorized or approved by the FDA. It has been cleared by the FDA under Emergency Use Clearance for use by authorized laboratories that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 USC Â§263a, and meet requirements for performing high complexity tests. Clarifi COVID-19 has been authorized only for the detection of SARS-CoV-2 nucleic acid, not for other viruses or pathogens, and is only authorized for the duration of the declaration of the existence of circumstances justifying authorization of emergency use in in vitro diagnostic tests for the detection and / or diagnosis of COVID-19 under section 564 (b) (1) of the statute, 21 USC Â§ 360bbb -3 (b) (1), unless the authorization is terminated or revoked earlier.